DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update November 28, 2023 Read
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 14, 2023 Read
Effect of DPI-125 on opioid withdrawal behaviors in rats: a comparison study with methadone and buprenorphine November 13, 2023 Read
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023 November 13, 2023 Read
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4) October 30, 2023 Read
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4) October 20, 2023 Read
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth October 19, 2023 Read
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus September 7, 2023 Read